Skip to main content

Table 3 Detailed pharmacokinetic parameters

From: Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial

 

CBS

cblC

CBS

cblC

CBS

cblC

100 mg/kg

100 mg/kg

250 mg/kg

250 mg/kg

Ratio 250/100

Ratio 250/100

N = 5

N = 5

N = 5

N = 6

N = 6

N = 6

AUCP,0-48 h,betaine (µmol h/L)

5522 [4909; 9317]

7485 [4843; 11907]

13,276 [6454; 14907]

10,389 [7826; 29243]

2.16 [1.30; 2.70]

1.32 [1.22; 2.46]

Cmax,betaine (µmol/L)

849 [681; 1048]

717 [585; 1000]

2074 [1001; 2563]

1136 [827; 2356]

2.80 [1.47; 3.00]

1.61 [1.17; 2.36]

Tmax,betaine (h)

2

2

2

2

  

CLbetaine/F (L/h kg−1)

0.15 [0.09; 0.17]

0.11 [0.07; 0.18]

0.16 [0.14; 0.33]

0.21 [0.07; 0.27]

  

Vss,betane/F (L kg−1)

1.45 [1.2; 1.98]

1.56 [1.04; 1.86]

1.29 [1.15; 3.41]

2.34 [1.15; 3.49]

  

t1/2, betaine

16.7 [13.8; 20.3]

18.3 [10.9; 24.2]

12.3 [10.0; 16.3]

18.4 [9.43; 25.9]

  

AUCP, 0–48 h, DMG (µmol h/L)

1627 [1149; 2496]

1408 [669; 2247]

2269 [1380; 7055]

2022 [1120; 2470]

1.51 [1.12; 2.99]

1.37 [1.08; 1.67]

Cmax,DMG (µmol/L)

77.4 [53.6; 169]

58.2 [31.9; 73.3]

106 [76.8; 288]

69.8 [42.1; 125.7]

1.43 [1.00; 4.12]

1.32 [1.08; 1.71]

Tmax,DMG (h)

6 [6; 24]

12 [6; 12]

12 [6; 12]

12 [6; 48]

  

t1/2,DMG

10.5 [8.82; 13.5]

19.5 [13.9; 25.1]

8.64 [7.39; 12.5]

16.0 [10.6; 25.5]

  
  1. Data are presented as mediane [min; max]. AUCP,0–48 h: Total area under the plasma concentration vs time curves from zero to 48 h; Cmax: Maximal concentration; Tmax: Time at maximal concentrations; CL/F CL: Apparent total body clearance; VSS: Apparent steady-state volume of distribution; t1/2: Half-life